REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Brain Repair Protocol

Cognitive Enhancementadvanced

80

synergy

80
Peptides

3

Avg Daily mcg

10,850

Level

advanced

Added

May 17, 2026

Overview

The Brain Repair Protocol represents the most aggressive peptide approach to neuroregeneration, combining a potent hepatocyte growth factor (HGF) mimetic with established neuroprotective peptides. Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a modified angiotensin IV analog that was discovered at Washington State University to be approximately 10 million times more potent than BDNF at promoting neuronal connectivity. It acts as an HGF/c-Met receptor agonist, stimulating the formation of new synaptic connections (synaptogenesis) and promoting the survival of existing neurons. In animal models of cognitive impairment, Dihexa restored learning and memory to levels comparable to young control animals. Semax provides complementary neuroprotection through BDNF/NGF upregulation and modulation of the melanocortin system in the brain. Its effects on neuroplasticity — the brain''s ability to form new neural pathways — make it an ideal companion to Dihexa''s synaptogenic activity. While Dihexa builds new connections, Semax ensures the molecular environment (neurotrophic factors, receptor density) supports the survival and strengthening of those connections through long-term potentiation mechanisms. BPC-157 is included for its documented neuroprotective effects, including modulation of the dopaminergic system, protection against excitotoxic damage (NMDA receptor modulation), and promotion of nerve growth factor expression. In animal models, BPC-157 has shown efficacy against traumatic brain injury, counteracted the effects of neurotoxins, and promoted peripheral nerve regeneration. The three-peptide combination addresses neuroregeneration from multiple angles: structural connectivity (Dihexa), neurotrophic environment (Semax), and neuroprotection/repair (BPC-157). This stack is classified as advanced and researcher-only due to Dihexa''s extreme potency, complete lack of human safety data, and theoretical concerns about its proliferative potential. It is not recommended without medical supervision and thorough risk assessment.

Dosing Protocol

Dihexa

Every day· oral

10,000 mcg

per dose

Semax

Every day· nasal

600 mcg

per dose

BPC-157

Every day· subcutaneous

250 mcg

per dose

Goals & Evidence

NeurogenesisMemory repairCognitive declineBrain injuryNeuroprotection
Evidence tier:Animal Studies

Warnings

  • Dihexa is a potent HGF mimetic with NO human trials. Extremely experimental. Semax has Russian approval. BPC-157 is Cat 2. This stack is for researchers only.

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.